Eli Lilly Closes AtaiBeckley Takeover, Delisting Nasdaq Shares and Cancelling MIAX Options
Published on 09/20/2026 at 14:51 | Editorial boerse-global.de
Eli Lilly has wrapped up its acquisition of AtaiBeckley, ending the biopharmaceutical company's run as a standalone public entity and shifting the focus of former shareholders squarely onto the mechanics of the cash payout and the contingent rights attached to the deal.
Shareholders approved the merger at a meeting on September 8, and the transaction was formally completed on September 11, turning AtaiBeckley into a wholly owned subsidiary of the pharmaceutical giant.
What Holders Receive
The agreement guarantees $6.75 per share in cash. On top of that sits a Contingent Value Right (CVR), a type of earn-out instrument that could deliver as much as an additional $2.50 per share if specified milestones are met. The structure pairs an immediate, certain payout with continued exposure to the pipeline's prospects.
That two-part design puts the initial equity valuation of the transaction at roughly $2.8 billion. Should every condition tied to the value rights be satisfied, the total package would climb to as much as $3.8 billion — the price of full access to the therapeutic portfolio for the buyer. Absent those achievements, the guaranteed cash component stands alone.
Should investors sell immediately? Or is it worth buying Atai Beckley?
Milestone Schedule
The first CVR tranche offers up to $1.00 per share, contingent on a Phase 3 trial for the drug candidate VLS-01 launching by September 11, 2030.
Whether that long-dated condition comes within reach hinges on ongoing work in treatment-resistant depression. In the Phase 2b Elumina study, the last patient was dosed on July 6. The trial randomized 156 patients, with initial topline data expected in the fourth quarter of 2026 — an early signal of how attainable the CVR terms may prove.
Delisting and Derivatives Wind-Down
The closing triggered a parallel retreat from public markets. AtaiBeckley filed Form 25 on September 11 to voluntarily delist its common stock from the Nasdaq, and the company intends to use Form 15 to formally terminate its reporting obligations with the U.S. Securities and Exchange Commission.
The derivatives market felt the change as well. On September 14, the exchange group MIAX cancelled options on AtaiBeckley across its MIAX Options, MIAX Pearl Options, MIAX Emerald Options and MIAX Sapphire Options venues.
Leadership turned over at completion: all sitting board members and senior officers stepped down, with representatives of an Eli Lilly subsidiary taking the reins. Filings show CFO Michael E. Faerm parted with all reported stock-based compensation as part of the integration, while director Laurent Fischer's option arrangements were dissolved and converted into cash payments and value rights under the merger terms.
The Science Lilly Is Buying
What drew Eli Lilly is AtaiBeckley's research focus: fast-acting neuroplastogens aimed at severe psychiatric conditions. The lead clinical effort is the BPL-003 program, targeting patients with treatment-resistant depression. Those programs will now advance under the umbrella of the new parent company, even as the developer's independent life on the capital markets comes to a close.
Ad
Atai Beckley Stock: New Analysis - 20 September
Fresh Atai Beckley information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
